Recent News

• 02.09.2026 - Can-Fite: Receives Canadian Patent Allowance for Namodenoson as an Anti-Obesity Therapy
• 02.05.2026 - Can-Fite: Patient with Decompensated Liver Cirrhosis Successfully Undergoes Liver Transplantation Following Treatment with Namodenoson
• 01.20.2026 - Can-Fite Completes Patient Enrollment in Phase 2a Pancreatic Cancer Study of Namodenoson
• 12.26.2025 - Can-Fite Granted Brazilian Patent for Treatment of Sexual Dysfunction
• 12.23.2025 - Can-Fite Announces Reverse Split of its Ordinary Shares and ADS Ratio Change
• 12.16.2025 - Can-Fite Provides Update on Clinical and Financial Status
• 11.26.2025 - Can-Fite’s Latest Developments of its Advanced Stage Drug Pipeline will be Presented at Noble Capital Markets 21st Annual Emerging Growth Equity Conference

Recent Filings

• 02.05.2026 - 6-K Report of foreign issuer [Rules 13a-16 and 15d-16]
• 02.05.2026 - EX-99.1 EX-99.1
• 01.27.2026 - 6-K Report of foreign issuer [Rules 13a-16 and 15d-16]
• 01.27.2026 - EX-99.1 EX-99.1
• 01.20.2026 - 6-K Report of foreign issuer [Rules 13a-16 and 15d-16]
• 01.20.2026 - EX-99.1 EX-99.1
• 01.16.2026 - 6-K Report of foreign issuer [Rules 13a-16 and 15d-16]
• 12.29.2025 - EX-99.1 EX-99.1
• 12.29.2025 - 6-K Report of foreign issuer [Rules 13a-16 and 15d-16]
• 12.23.2025 - EX-99.1 EX-99.1